FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Stem Cells Dev / Steps Toward Standardized In Vitro Assessment of Immunomodul...
Stem cells and development2021; 31(1-2); 18-25; doi: 10.1089/scd.2021.0189

Steps Toward Standardized In Vitro Assessment of Immunomodulatory Equine Mesenchymal Stromal Cells Before Clinical Application.

Abstract: Inflammation-associated disorders are significant causes of morbidity in horses. Equine single-donor mesenchymal stromal cells (sdMSCs) hold promise as cell-therapy candidates due to their secretory nonprogenitor functions. This has been demonstrated by mononuclear cell suppression assays (MSAs) showing that sdMSCs are blood mononuclear cell (BMC) suppressive in vitro. sdMSCs derived from umbilical cord blood are of clinical interest due to their ease of procurement, multipotency, and immunomodulatory ability. Due to the inherent donor-to-donor heterogeneity of MSCs, the development of robust and easily deployable methods of potency assessment is critical for improving MSCs' predictability in treating inflammatory diseases. This study focuses on the development of robust in vitro potency assays and the assessment of potential sdMSC therapeutic end products generated from pooled sdMSCs (pMSCs). We hypothesized that, compared to MSA using only one donor, MSA using pooled BMCs (pBMCs) is a more robust sdMSC potency assay due to reduced donor BMC heterogeneity. pBMCs were generated by pooling equine BMCs isolated from peripheral blood of five donors in equal ratios. pBMCs were labeled with carboxyfluorescein succinimidyl ester (CFSE) and stored in liquid nitrogen until use. Similarly, pooling sdMSCs from multiple equine donors in equal ratios generated pMSCs. sdMSC cultures were assessed with pBMCs in MSA using Bromodeoxyuridine ELISA and CFSE. Proliferation assessment of BMCs from individual donors revealed varied responses to concanavalin A (ConA) stimulation. MSA using BMCs from single donors further demonstrated BMC donor variability. Utilizing this assay, we have also found that the immunosuppressive potencies of pMSCs are at least equal, if not more, than the calculated mean of individual cultures. MSA based on pBMCs provides a consistent and reproducible equine sdMSC potency assay. This knowledge could be used in production monitoring of cellular potency and as release criteria before clinical use.
Get Full Text
Publication Date: 2021-12-03 PubMed ID: 34779250PubMed Central: PMC8792491DOI: 10.1089/scd.2021.0189Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Equine single-donor mesenchymal stromal cells (sdMSCs) show potential for cell-therapy application because of their immunomodulatory properties. However, variations among donors complicate the standardization of potency assessments, affecting the predictability of these cells in treating inflammatory diseases. The research paper suggests an alternative method, using pooled blood mononuclear cells (pBMCs) instead of individual donor cells, for more consistent in vitro potency assays.

Objective and Hypothesis

  • The study’s objective was to develop robust and easily deployable in vitro methods for assessing sdMSCs’ potency before using them in clinical treatments for inflammation-associated diseases in horses.
  • The primary hypothesis was that using pooled blood mononuclear cells (pBMCs) — a mixture collected from multiple donors — in mononuclear cell suppression assays (MSAs) would yield more robust results than using cells from a single donor, due to the reduced variability inherent in the former method.

Methods

  • The researchers created pBMCs by combining blood mononuclear cells isolated from the peripheral blood of five different donors in equal ratios.
  • Similarly, to produce pooled sdMSCs (pMSCs), they mixed sdMSCs from multiple donors, also in equal ratios.
  • Both pBMCs and pMSCs were labeled with carboxyfluorescein succinimidyl ester (CFSE) and stored in liquid nitrogen.
  • Various assays assessed the suppressive potential of these cells, including mononuclear cell suppression assays (MSAs), Bromodeoxyuridine ELISAs, and tests using Concanavalin A stimulation.

Findings

  • The researchers found varied responses to Concanavalin A stimulation in the proliferation assessment of BMCs from individual donors, suggesting donor variability could complicate potency assessments.
  • The use of pBMCs in the MSAs allowed for consistency and reproducibility in evaluating the potency of equine sdMSCs.
  • In addition, testing showed the immunosuppressive potencies of pMSCs were at least on par, if not better than, the calculated mean of individual cultures.

Significance

  • This study not only suggests a solution to the variability challenge in sdMSC potency assessments but also provides a reliable procedure to test future cellular products before clinical application. This will enhance treatment predictability for inflammation-associated disorders in horses.
  • The researchers suggest this potency-assessment method could be used for production control and as part of the release criteria before clinical use.

Cite This Article

APA
Lee OJ, Koch TG. (2021). Steps Toward Standardized In Vitro Assessment of Immunomodulatory Equine Mesenchymal Stromal Cells Before Clinical Application. Stem Cells Dev, 31(1-2), 18-25. https://doi.org/10.1089/scd.2021.0189

Publication

Stem cells and development
ISSN: 1557-8534
NlmUniqueID: 101197107
Country: United States
Language: English
Volume: 31
Issue: 1-2
Pages: 18-25

Researcher Affiliations

Lee, Olivia J
  • Department of Biomedical Sciences, University of Guelph, Guelph, Canada.
Koch, Thomas G
  • Department of Biomedical Sciences, University of Guelph, Guelph, Canada.

MeSH Terms

  • Animals
  • Cell Proliferation / physiology
  • Cells, Cultured
  • Fetal Blood
  • Horses
  • Immunomodulation
  • Leukocytes, Mononuclear
  • Mesenchymal Stem Cells

References

This article includes 30 references
  1. Lacourt M, Gao C, Li A, Girard C, Beauchamp G, Henderson JE, Laverty S. Relationship between cartilage and subchondral bone lesions in repetitive impact trauma-induced equine osteoarthritis.. Osteoarthritis Cartilage 2012 Jun;20(6):572-83.
    pubmed: 22343573doi: 10.1016/j.joca.2012.02.004google scholar: lookup
  2. MacDonald ES, Barrett JG. The Potential of Mesenchymal Stem Cells to Treat Systemic Inflammation in Horses.. Front Vet Sci 2019;6:507.
    pmc: PMC6985200pubmed: 32039250doi: 10.3389/fvets.2019.00507google scholar: lookup
  3. Lee OJ, Luk F, Korevaar SS, Koch TG, Baan CC, Merino A, Hoogduijn MJ. The Importance of Dosing, Timing, and (in)Activation of Adipose Tissue-Derived Mesenchymal Stromal Cells on Their Immunomodulatory Effects.. Stem Cells Dev 2020 Jan 1;29(1):38-48.
    pubmed: 31696786doi: 10.1089/scd.2019.0225google scholar: lookup
  4. Williams LB, Koenig JB, Black B, Gibson TW, Sharif S, Koch TG. Equine allogeneic umbilical cord blood derived mesenchymal stromal cells reduce synovial fluid nucleated cell count and induce mild self-limiting inflammation when evaluated in an lipopolysaccharide induced synovitis model.. Equine Vet J 2016 Sep;48(5):619-25.
    pubmed: 26114736doi: 10.1111/evj.12477google scholar: lookup
  5. Williams LB, Co C, Koenig JB, Tse C, Lindsay E, Koch TG. Response to Intravenous Allogeneic Equine Cord Blood-Derived Mesenchymal Stromal Cells Administered from Chilled or Frozen State in Serum and Protein-Free Media.. Front Vet Sci 2016;3:56.
    pmc: PMC4956649pubmed: 27500136doi: 10.3389/fvets.2016.00056google scholar: lookup
  6. Parel Y, Chizzolini C. CD4+ CD8+ double positive (DP) T cells in health and disease.. Autoimmun Rev 2004 Mar;3(3):215-20.
    pubmed: 15110234doi: 10.1016/j.autrev.2003.09.001google scholar: lookup
  7. Martin I, Galipeau J, Kessler C, Le Blanc K, Dazzi F. Challenges for mesenchymal stromal cell therapies.. Sci Transl Med 2019 Feb 20;11(480).
    pubmed: 30787168doi: 10.1126/scitranslmed.aat2189google scholar: lookup
  8. Fričová D, Korchak JA, Zubair AC. Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinson's disease.. NPJ Regen Med 2020 Nov 3;5(1):20.
    pmc: PMC7641157pubmed: 33298940doi: 10.1038/s41536-020-00106-ygoogle scholar: lookup
  9. Robb KP, Fitzgerald JC, Barry F, Viswanathan S. Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency.. Cytotherapy 2019 Mar;21(3):289-306.
    pubmed: 30528726doi: 10.1016/j.jcyt.2018.10.014google scholar: lookup
  10. Wagner W, Feldmann RE Jr, Seckinger A, Maurer MH, Wein F, Blake J, Krause U, Kalenka A, Bürgers HF, Saffrich R, Wuchter P, Kuschinsky W, Ho AD. The heterogeneity of human mesenchymal stem cell preparations--evidence from simultaneous analysis of proteomes and transcriptomes.. Exp Hematol 2006 Apr;34(4):536-48.
    pubmed: 16569600doi: 10.1016/j.exphem.2006.01.002google scholar: lookup
  11. Viswanathan S, Keating A, Deans R, Hematti P, Prockop D, Stroncek DF, Stacey G, Weiss DJ, Mason C, Rao MS. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation.. Stem Cells Dev 2014 Jun 1;23(11):1157-67.
    pmc: PMC4027980pubmed: 24422625doi: 10.1089/scd.2013.0591google scholar: lookup
  12. Yang ZX, Han ZB, Ji YR, Wang YW, Liang L, Chi Y, Yang SG, Li LN, Luo WF, Li JP, Chen DD, Du WJ, Cao XC, Zhuo GS, Wang T, Han ZC. CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties.. PLoS One 2013;8(3):e59354.
    pmc: PMC3595282pubmed: 23555021doi: 10.1371/journal.pone.0059354google scholar: lookup
  13. Kabat M, Bobkov I, Kumar S, Grumet M. Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?. Stem Cells Transl Med 2020 Jan;9(1):17-27.
    pmc: PMC6954709pubmed: 31804767doi: 10.1002/sctm.19-0202google scholar: lookup
  14. Lepage SIM, Lee OJ, Koch TG. Equine Cord Blood Mesenchymal Stromal Cells Have Greater Differentiation and Similar Immunosuppressive Potential to Cord Tissue Mesenchymal Stromal Cells.. Stem Cells Dev 2019 Feb 1;28(3):227-237.
    pubmed: 30484372doi: 10.1089/scd.2018.0135google scholar: lookup
  15. Kuçi Z, Bönig H, Kreyenberg H, Bunos M, Jauch A, Janssen JW, Škifić M, Michel K, Eising B, Lucchini G, Bakhtiar S, Greil J, Lang P, Basu O, von Luettichau I, Schulz A, Sykora KW, Jarisch A, Soerensen J, Salzmann-Manrique E, Seifried E, Klingebiel T, Bader P, Kuçi S. Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey.. Haematologica 2016 Aug;101(8):985-94.
    pmc: PMC4967578pubmed: 27175026doi: 10.3324/haematol.2015.140368google scholar: lookup
  16. Ketterl N, Brachtl G, Schuh C, Bieback K, Schallmoser K, Reinisch A, Strunk D. A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance.. Stem Cell Res Ther 2015 Dec 1;6:236.
    pmc: PMC4666276pubmed: 26620155doi: 10.1186/s13287-015-0233-8google scholar: lookup
  17. Wieczorek L, Brown BK, Delsarto Macedo C, Wesberry-Schmierer M, Ngauy V, Rosa Borges A, Michael NL, Marovich MA, Montefiori DC, Polonis VR. Mitigation of variation observed in a peripheral blood mononuclear cell (PBMC) based HIV-1 neutralization assay by donor cell pooling.. Virology 2013 Dec;447(1-2):240-8.
    pubmed: 24210120doi: 10.1016/j.virol.2013.09.014google scholar: lookup
  18. Lai-Hipp C, Goldberg T, Scott E, Ziman A, Vyas G. Pooled peripheral blood mononuclear cells provide an optimized cellular substrate for human immunodeficiency virus Type 1 isolation during acute infection.. Transfusion 2011 Feb;51(2):333-7.
    pubmed: 20796251doi: 10.1111/j.1537-2995.2010.02831.xgoogle scholar: lookup
  19. Silva C, Santa C, Anjo SI, Manadas B. A reference library of peripheral blood mononuclear cells for SWATH-MS analysis.. Proteomics Clin Appl 2016 Jul;10(7):760-4.
    pubmed: 27188786doi: 10.1002/prca.201600070google scholar: lookup
  20. Gupta PK, Krishna M, Chullikana A, Desai S, Murugesan R, Dutta S, Sarkar U, Raju R, Dhar A, Parakh R, Jeyaseelan L, Viswanathan P, Vellotare PK, Seetharam RN, Thej C, Rengasamy M, Balasubramanian S, Majumdar AS. Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger's Disease: Phase II Study Report Suggests Clinical Efficacy.. Stem Cells Transl Med 2017 Mar;6(3):689-699.
    pmc: PMC5442769pubmed: 28297569doi: 10.5966/sctm.2016-0237google scholar: lookup
  21. François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J. Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-γ licensing.. Cytotherapy 2012 Feb;14(2):147-52.
    pmc: PMC3279133pubmed: 22029655doi: 10.3109/14653249.2011.623691google scholar: lookup
  22. Galipeau J. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2013 Jan;15(1):2-8.
    pubmed: 23260081doi: 10.1016/j.jcyt.2012.10.002google scholar: lookup
  23. Kuçi Z, Seiberth J, Latifi-Pupovci H, Wehner S, Stein S, Grez M, Bönig H, Köhl U, Klingebiel T, Bader P, Kuçi S. Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression.. Haematologica 2013 Oct;98(10):1609-16.
    pmc: PMC3789467pubmed: 23975178doi: 10.3324/haematol.2013.092700google scholar: lookup
  24. Widholz B, Tsitlakidis S, Reible B, Moghaddam A, Westhauser F. Pooling of Patient-Derived Mesenchymal Stromal Cells Reduces Inter-Individual Confounder-Associated Variation without Negative Impact on Cell Viability, Proliferation and Osteogenic Differentiation.. Cells 2019 Jun 24;8(6).
    pmc: PMC6628337pubmed: 31238494doi: 10.3390/cells8060633google scholar: lookup
  25. Bochkov NP, Nikitina VA, Buyanovskaya OA, Voronina ES, Goldstein DV, Kuleshov NP, Rzhaninova AA, Chaushev IN. Aneuploidy of stem cells isolated from human adipose tissue.. Bull Exp Biol Med 2008 Sep;146(3):344-7.
    pubmed: 19240856doi: 10.1007/s10517-008-0293-1google scholar: lookup
  26. Izadpanah R, Kaushal D, Kriedt C, Tsien F, Patel B, Dufour J, Bunnell BA. Long-term in vitro expansion alters the biology of adult mesenchymal stem cells.. Cancer Res 2008 Jun 1;68(11):4229-38.
    pmc: PMC2713721pubmed: 18519682doi: 10.1158/0008-5472.CAN-07-5272google scholar: lookup
  27. de Witte SFH, Luk F, Sierra Parraga JM, Gargesha M, Merino A, Korevaar SS, Shankar AS, O'Flynn L, Elliman SJ, Roy D, Betjes MGH, Newsome PN, Baan CC, Hoogduijn MJ. Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells.. Stem Cells 2018 Apr;36(4):602-615.
    pubmed: 29341339doi: 10.1002/stem.2779google scholar: lookup
  28. Deskins DL, Bastakoty D, Saraswati S, Shinar A, Holt GE, Young PP. Human mesenchymal stromal cells: identifying assays to predict potency for therapeutic selection.. Stem Cells Transl Med 2013 Feb;2(2):151-8.
    pmc: PMC3659751pubmed: 23362238doi: 10.5966/sctm.2012-0099google scholar: lookup
  29. Li M, Khong D, Chin LY, Singleton A, Parekkadan B. Therapeutic Delivery Specifications Identified Through Compartmental Analysis of a Mesenchymal Stromal Cell-Immune Reaction.. Sci Rep 2018 May 1;8(1):6816.
    pmc: PMC5931547pubmed: 29717209doi: 10.1038/s41598-018-24971-2google scholar: lookup
  30. Duijvestein M, Wildenberg ME, Welling MM, Hennink S, Molendijk I, van Zuylen VL, Bosse T, Vos AC, de Jonge-Muller ES, Roelofs H, van der Weerd L, Verspaget HW, Fibbe WE, te Velde AA, van den Brink GR, Hommes DW. Pretreatment with interferon-γ enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis.. Stem Cells 2011 Oct;29(10):1549-58.
    pubmed: 21898680doi: 10.1002/stem.698google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,383 horse owners like you who receive our email updates on horse health and nutrition.